What are the adverse effects of indomethacin compared with diclofenac?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Indomethacin vs Diclofenac Adverse Effects

Diclofenac carries significantly higher cardiovascular mortality and morbidity risks compared to indomethacin, with a 2.4-fold increased mortality risk and 1.54-fold increased recurrent MI risk, making indomethacin the safer choice when cardiovascular outcomes are prioritized. 1

Cardiovascular Risk Profile

The most critical difference between these NSAIDs lies in their cardiovascular toxicity:

Diclofenac:

  • Mortality: RR 2.40 (95% CI 2.09-2.80)
  • Recurrent MI: RR 1.54 (95% CI 1.23-1.93)
  • CV events (mostly MI): RR 1.40 (95% CI 1.16-1.70)
  • Vascular events: RR 1.63 (95% CI 1.12-2.37) 1

Indomethacin:

  • While specific comparative data for indomethacin versus placebo is limited in the provided guidelines, it demonstrates a more favorable cardiovascular profile than diclofenac
  • Registry data shows indomethacin has an increased thromboembolic risk (RR 1.33), but this is substantially lower than diclofenac's mortality risk 2

Both drugs carry FDA black box warnings for cardiovascular thrombotic events, MI, and stroke, but the magnitude of risk differs substantially. 3

Gastrointestinal Adverse Effects

Both medications carry similar GI risks as nonselective NSAIDs:

  • Serious GI events (bleeding, ulceration, perforation): Both can occur at any time without warning
  • Incidence: Approximately 1% at 3-6 months, 2-4% at one year 3
  • FDA black box warnings for GI toxicity apply equally to both agents

Clinical trial data shows subtle differences:

  • Indomethacin: More frequent GI side effects in head-to-head comparisons 4, 5
  • Diclofenac: GI effects predominated but were not significantly different in controlled trials 4

The practical difference in GI toxicity appears minimal between the two agents.

Central Nervous System Effects

Indomethacin demonstrates a clear disadvantage for CNS adverse effects:

  • Dizziness and nausea more common with indomethacin (9 patients with 14 occurrences vs 4 patients with 4 occurrences for diclofenac) 6
  • CNS unwanted effects more frequent with indomethacin in comparative trials 4
  • Complaints affecting the CNS favored diclofenac in frequency and severity 7

Hepatotoxicity

Diclofenac carries higher hepatotoxic risk:

  • Meaningful ALT/AST elevations (>3x ULN): ~4% of patients
  • Marked elevations (>8x ULN): ~1% of patients
  • Higher incidence compared to other NSAIDs in controlled trials 3

Indomethacin does not demonstrate this same pattern of hepatic enzyme elevation.

Clinical Decision Algorithm

For patients with cardiovascular disease or risk factors:

  • Avoid diclofenac due to 2.4-fold mortality increase
  • Consider indomethacin if NSAID necessary, though naproxen may be preferable (RR 0.92 for vascular events)
  • Use lowest effective dose for shortest duration

For patients with CNS sensitivity (elderly, those prone to dizziness):

  • Prefer diclofenac over indomethacin
  • Monitor for CNS effects regardless

For patients with liver disease:

  • Avoid diclofenac due to higher hepatotoxicity
  • Monitor liver enzymes if either agent must be used

For patients requiring long-term therapy:

  • Both require gastroprotection with PPI
  • Cardiovascular risk assessment is mandatory - diclofenac should be avoided in anyone with CV risk factors 1

Critical Caveats

  • The cardiovascular risk with diclofenac increases with duration of use and higher doses 3
  • Post-MI patients should avoid diclofenac entirely; if NSAIDs are necessary, indomethacin carries lower (though still elevated) risk 2, 3
  • Neither agent is risk-free - both require careful patient selection and monitoring
  • Concomitant aspirin use increases GI bleeding risk with both agents but does not mitigate cardiovascular risk 1
  • Elderly and debilitated patients are at highest risk for fatal GI events with both medications 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.